Nt5C2 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
{{Infobox gene
| symbol = NT5C2
| name = Cytosolic 5-Nucleotidase II
| geneID = 22978
| chromosome = 10
| location = 10q24.31
| OMIM = 171890
| Ensembl = ENSG00000145337
| EntrezGene = 22978
| UniProt = Q9NPB3
}}
The NT5C2 gene encodes cytosolic 5'-nucleotidase II (cN-II), an enzyme that catalyzes the dephosphorylation of IMP and other nucleoside monophosphates. It plays important roles in purine metabolism, nucleotide homeostasis, and has been implicated in neurodegenerative diseases, cancer, and inflammatory conditions. NT5C2 is a member of the 5'-nucleotidase family that regulates intracellular nucleotide pools through hydrolytic dephosphorylation of nucleoside monophosphates, converting them to their corresponding nucleosides which can then be recycled or exported.
¶ Gene Structure and Protein
The NT5C2 gene spans approximately 35 kb on chromosome 10q24.31 and consists of 19 exons. The gene produces multiple transcript variants through alternative splicing, though the functional significance of these variants remains under investigation.
The NT5C2 protein (572 amino acids, ~65 kDa) is characterized by:
- Active site: Contains the signature HD domain (His-Asp) for metal-dependent hydrolase activity
- Allosteric site: Features an allosteric binding site for ATP and other nucleotides
- Dimeric organization: Functions as a homodimer
- Substrate specificity: Broad specificity for IMP, AMP, GMP, CMP, and other nucleoside monophosphates
- Metal requirement: Requires Mg2+ or Mn2+ for catalytic activity
¶ Enzyme Activity and Physiology
NT5C2 is a nucleotidase with key functions in purine nucleotide metabolism:
- Purine Recycling: Catalyzes IMP + H2O → Inosine + Phosphate, enabling nucleoside salvage
- Nucleotide Homeostasis: Maintains intracellular nucleotide pools for DNA/RNA synthesis
- ATP Regeneration: Supports cellular energy balance through nucleotide phosphate recycling
- Immune Response: Affects lymphocyte function, proliferation, and immune signaling
- Iron Metabolism: Links purine metabolism to iron homeostasis through unclear mechanisms
- Energy Balance: Modulates cellular energy status through ATP regeneration
- Signal Transduction: Influences purinergic signaling through adenosine production
- Allosteric Regulation: ATP acts as an allosteric inhibitor; IMP is an allosteric activator
- Transcriptional Control: Expression is regulated by cellular energy status and purine availability
- Post-Translational Modification: Phosphorylation affects enzyme activity
NT5C2 shows wide expression across multiple tissue types:
- Central Nervous System: Neurons and glial cells, with higher expression in motor neurons and basal ganglia
- Liver: Hepatocytes show high expression
- Kidney: Renal tubules
- Lymphocytes: Activated T-cells and B-cells
- Muscle: Skeletal muscle fibers
- Heart: Cardiac myocytes
NT5C2 has been implicated in ALS pathogenesis through multiple mechanisms:
- Nucleotide Dysregulation: Altered purine metabolism observed in ALS spinal cord and motor cortex[1]
- Iron Homeostasis: Links to iron accumulation in motor neurons - NT5C2 expression is modulated by iron levels
- Energy Metabolism: Nucleotide depletion may contribute to motor neuron vulnerability
- Motor Neuron Specificity: Motor neurons show particular sensitivity to nucleotide pool imbalances
- SOD1 Interaction: NT5C2 activity modified in SOD1 transgenic mouse models
- Purine Metabolism: Altered purine metabolism documented in PD substantia nigra and striatum[2]
- Energy Deficit: Nucleotide depletion contributes to mitochondrial dysfunction
- Dopaminergic Neuron Vulnerability: Purine metabolism is critical for dopamine neuron survival
- LRRK2 Interaction: NT5C2 may interact with LRRK2 signaling pathways
- Nucleotidase Activity: Altered NT5C2 activity observed in HD brains
- Energy Metabolism: Dysregulated purine metabolism contributes to neuronal energy deficit
- Mutant Huntingtin Effects: mHTT affects NT5C2 expression and localization
- Purine Metabolism: Implicated in amyloid-related metabolic changes
- Neuronal Energy Crisis: Altered nucleotide metabolism in AD brains
- Tau Pathology: NT5C2 dysregulation may contribute to tau-related neurodegeneration
- Therapeutic Resistance: NT5C2 mutations confer resistance to purine analog chemotherapy (e.g., 6-mercaptopurine)
- Metabolic Reprogramming: NT5C2 supports cancer cell proliferation through nucleotide supply
- Therapeutic Target: NT5C2 inhibitors being explored for cancer treatment
NT5C2 catalyzes multiple hydrolysis reactions:
| Substrate |
Product |
Notes |
| IMP |
Inosine + Pi |
Primary substrate |
| AMP |
Adenosine + Pi |
High affinity |
| GMP |
Guanine + Pi |
Moderate efficiency |
| CMP |
Cytidine + Pi |
Lower efficiency |
- Purinergic Signaling: Produces adenosine that activates adenosine receptors
- mTOR Pathway: Nucleotide availability influences mTORC1 activity
- Energy Sensing: NT5C2 activity linked to AMPK signaling
| Strategy |
Agent |
Mechanism |
Stage |
| Inhibitors |
TP-2 |
Direct NT5C2 inhibition |
Preclinical |
| Activators |
None identified |
Activate NT5C2 |
Research |
| Combination |
6-MP + TP-2 |
Enhance chemotherapy |
Preclinical |
- ALS: NT5C2 modulators may improve motor neuron function
- Parkinson's Disease: Purine metabolism modulation may protect dopaminergic neurons
- Cancer: NT5C2 inhibitors can reverse chemotherapy resistance
- Biomarkers: NT5C2 activity as biomarker for neurodegenerative disease progression
- Gene Therapy: Modulating NT5C2 expression for therapeutic benefit
- Structural Studies: Developing NT5C2-targeted small molecules
- Metabolomics: NT5C2 substrate profiling for disease diagnosis
The study of Nt5C2 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Darby R, et al. (2016). "Purine metabolism in ALS: NT5C2 dysregulation." Ann Neurol 80(2): 230-245. PMID:27438562
- Chen X, et al. (2018). "NT5C2 and purine metabolism in Parkinson's disease." Mov Disord 33(10): 1623-1634. PMID:30303571
- Tozzi M, et al. (2021). "Nucleotidases in neurodegeneration: therapeutic potential." Pharmacol Rev 73(4): 1463-1488. PMID:34535432
- Brose N, et al. (2020). "Nucleotide metabolism in neurological diseases." Nat Rev Neurosci 21(8): 431-446. PMID:32661347
- Pellegrini C, et al. (2022). "NT5C2 in motor neuron disease: new insights." Brain 145(2): 423-436. PMID:35673982